Pfizer and BioNTech will begin trials of their updated mRNA Covid-19 vaccine designed to protect against the newer BA.4 and BA.5 sub-variants of the coronavirus later this month.
for the second quarter of 2022, where the German vaccine maker reported a total revenue of €3.2 billion —lower than analyst estimates.
BioNTech and its American partner Pfizer have started manufacturing “bivalent” Omicron BA.1 and BA.4/BA.5 vaccines that will offer protections both against the fast spreading newer variants and earlier variants, the company said. The company claims it will be able roll out the updated shots by October—in time for potential fall boosters—if it receives regulatory approval.
Pfizer and BioNTech have already carried out clinical trials for their BA.1 Omicron-focussed vaccine—it was shown to produce higher neutralizing antibodies against the variant—and have submitted the findings to regulators.submit updated clinical trial data for the BA.4/BA.5 adapted shots. The agency will instead approve the modified vaccines using clinical data from the BA.1 vaccine trials. This will allow the updated vaccines to be approved quicker.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln dealPfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics , as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.
Read more »
Pfizer Agrees to $5.4 Billion Deal for Global Blood TherapeuticsPfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Read more »
Pfizer buying spree continues with $5.4B hematology dealPfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Read more »
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJPfizer Inc. undefined has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal...
Read more »
BioNTech reports strong first half, expects demand to growBERLIN (AP) — BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year and expects demand to grow as it releases updated vaccines to target new omicron strains .
Read more »
‘Self-Boosting’ Vaccines Could Be Immunizations of the FutureMIT researchers have developed microparticles that could be used to create self-boosting vaccines, saving us time and money, and better curbing the spread of germs.
Read more »